Navigation Links
AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
Date:12/28/2007

MARKHAM, ON, Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX - News), a leader in the development of Nanotechnology for Drug Delivery Platforms, announce that in order to meet TSX Venture Exchange listing requirements, its CEO, CFO, directors, consultants and employees plan to exercise stock options to purchase 3,300,000 shares of AlphaRx common stock. Michael Lee, President and CEO, will cancel 6,000,000 options granted to him in 2004 which carried a strike price of $0.15 a share and will exercise 1,862,228 warrants with a strike price of $0.10 a shares. Furthermore, certain company employees will voluntarily cancel 1,710,000 of their options at the same time to make the capital structure of the company more attractive for institutional investors. The company expects to complete these transactions on or before Dec 31, 2007.

In conjunction of the above transactions, Michael Lee will purchase 6,000,000 company shares at a price of $0.15 a share under a private placement. The company expects to close this private placement on or before January 31, 2008.

The shares issued from the exercise of options, warrants and the private placement are subject to applicable hold periods and trading restrictions under the US Securities Act of 1933 and may only be offered, sold or otherwise transferred outside the US or inside the US in accordance with applicable exemptions from registration.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx To Present at 47th Annual ICAAC
2. AlphaRx Announces Debt Conversion
3. Ohio Dental Association Installs New President and Officers
4. HealthInsuranceFinders.com Launches Video Contest for Young Directors
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
7. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
8. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
9. Patient Safety Authority Board of Directors Names Infection Advisory Panel
10. William Moore Appointed to IRIDEX Board of Directors
11. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
Breaking Medicine Technology: